RVMD BeOne Deal: RAS(ON) Portfolio, Funded Phase 3

Revolution Medicines (RVMD) and BeOne Medicines (ONC) announced a multi-part collaboration on August 10 that pairs BeOne’s oncology pipeline with RVMD’s four clinical-stage RAS(ON) inhibitors, grants BeOne exclusive Asian commercialization rights, and includes a BeOne-funded global registrational Phase 3 study. RVMD closed at $206.97 on Friday with a $44 billion market cap. The stock was up roughly 1% pre-market.

The clinical collaboration will test combinations of BeOne’s BGB-58067, an MTA-cooperative PRMT5 inhibitor, and BG-T187, an EGFR x MET trispecific antibody, with RVMD’s four oral RAS(ON) inhibitors: daraxonrasib (multi-selective, NDA under FDA review for pancreatic cancer), zoldonrasib (G12D-selective, Breakthrough Therapy Designation in NSCLC), elironrasib (G12C-selective), and RMC-5127 (G12V-selective, entering the clinic).

The regional rights deal gives BeOne exclusive development and commercialization rights across select Asian markets. RVMD retains full rights in the US, Europe, Japan, and Korea, the highest-value oncology markets. RVMD receives development and sales milestones plus tiered royalties on Asian net sales. BeOne also agreed to fund and run a global registrational Phase 3 study for one of the four RAS(ON) inhibitors using its internal development infrastructure, freeing RVMD’s balance sheet from one of its multiple planned registrational trials.

BeOne, formerly BeiGene, brings three advantages. It has a deep oncology pipeline with assets in complementary pathways. It runs a fully integrated development “superhighway” that has shepherded five internally discovered drugs to global approvals. And it has the commercial infrastructure across Asia, including China under its NRDL reimbursement framework, to commercialize these drugs in markets where RVMD has no footprint. BeOne separately disclosed plans to advance a CNS-penetrant RAS(ON) inhibitor and a KRAS degrader into the clinic before year-end, signaling the RAS franchise is a strategic priority, not a one-off license.

The deal validates RVMD’s RAS(ON) platform with a partner that could have built competing RAS programs internally. Instead, BeOne is paying to access RVMD’s molecules and funding a Phase 3 trial. That is a signal about how differentiated the tri-complex inhibitor platform looks to oncology peers.

The risk is execution. RVMD now has a partner-dependent registrational study running alongside its own three ongoing Phase 3 trials (RASolute 302, 303, 304) and the daraxonrasib NDA review under the CNPV accelerated pathway. The company burned $454 million in Q1 2026 with no revenue. A partner-funded trial reduces capital intensity but adds coordination complexity. For more on the daraxonrasib regulatory path, see the RVMD daraxonrasib NDA analysis.

Source: Revolution Medicines press release, August 10, 2026 · BeOne/RevMed AFP coverage